Improved Survival of Cardiac Transplantation Candidates with Implantable Cardioverter Defibrillator Therapy:

Abstract

ICD therapy is associated with improved survival in high-risk cardiac transplant candidates, and ICD benefit appears to be independent of concomitant treatment.

Sudden Death Prior to Pediatric Heart Transplantation: Would Implantable Defibrillators Improve Outcome?

“…In another study of 310 consecutive patients referred for transplant at the University of Minnesota, Ermis et al reported a significant benefit of ICD therapy with regard to total mortality. 18 In their study, the 1-year mortality among pre-transplant patients with an ICD was only 7%, compared with 31% mortality among those without an ICD.…”

The Burden of Acute Renal Failure in Nonrenal Solid Organ Transplantation

“…The incidence of acute renal failure has varied widely across studies (4,9,14,(17)(18)(19)(20)(21), in part because of the inclusion of patients from early in the evolution of clinical practice. It is unclear whether the incidence of acute renal failure and its relationship to outcomes have been altered by changes in clinical transplantation, including improvements in graft and patient survival, increasing use of living donors, and expansion of eligibility criteria for both donors and recipients (22)(23)(24)(25)(26)(27)(28)(29)(30). The purpose of this study was to explore the incidence of acute renal failure and its impact on mortality and morbidity in a contemporary cohort of patients undergoing liver and thoracic organ transplantation.…”

HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials

“…[36][37][38][39][40][41] However, most of these studies are fairly small and nonrandomized. There are certainly no data to support ICD therapy in patients within 40 days of an MI who are waiting for cardiac transplant.…”

“…[36][37][38][39] In an analysis of 310 patients awaiting transplant at the University of Minnesota, the overall mortality in ICD patients was 22% compared with 60.2% in non-ICD patients, and both ICD implant and beta-blockade were protective. 38 Survival at 6 months and at 1, 2, 3, and 4 years was significantly improved in ICD patients (P=.0001). In an analysis of 854 patients awaiting transplant in Europe and with a median follow-up of 4.7 months, total mortality in ICD patients was 11.8% compared with 21.5% in non-ICD patients (P=.03).…”